Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Familial amyloidosis of the Finnish type (FAF) is a rare multisystemic disorder caused by mutations in the gelsolin gene. The clinical presentation is typically characterised by a triad of ophthalmic, neurological and dermatological findings. FAF has been reported in several countries, primarily in Finland and recently in Portugal. We report the first genetically confirmed cases of FAF from two unrelated families in our neuromuscular outpatient clinic. Gelsolin gene sequencing revealed the heterozygous gelsolin mutation (c.640G>A). The clinical features and the neurophysiological studies of two index patients and their relatives are presented. Obtaining an early diagnosis can be challenging, but FAF should be considered in the differential diagnosis of progressive bilateral facial neuropathy, even if there is no known Finnish ancestor.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668035 | PMC |
| http://dx.doi.org/10.1136/bcr-2021-245764 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tofacitinib for the Treatment of Primary Localized Cutaneous Amyloidosis.
J Dermatol
September 2025
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Primary localized cutaneous amyloidosis (PLCA) is a chronic skin disorder that can cause persistent pruritus and cosmetic disfigurement and remains challenging to treat. Tofacitinib, an oral Janus kinase inhibitor, has shown potential therapeutic benefits for PLCA. We conducted a retrospective study of 24 patients with PLCA treated with tofacitinib (10 mg/day) at our dermatology clinic.
View Article and Find Full Text PDFA new screening tool for early recognition of ATTRv polyneuropathy in clinical practice: AmyloScan.
J Neurol
September 2025
Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus D, 24105, Kiel, Germany.
Hereditary transthyretin (ATTRv) amyloidosis is a progressive multisystem disorder, mainly characterized by cardiac dysfunction and polyneuropathy. Due to its rarity and heterogeneous presentation, diagnosis is often delayed, which has a direct impact on the initiation of treatment and, therefore, span and quality of life. To facilitate early disease recognition, we aimed to develop and validate a new screening tool for early identification of ATTRv amyloidosis with polyneuropathy (AmyloScan).
View Article and Find Full Text PDFA Novel Case of Nerve Biopsy Proven Wild Type Transthyretin (TTR) Amyloidosis.
J Peripher Nerv Syst
September 2025
Mayo Clinic Department of Neurology, Rochester, Minnesota, USA.
Aim: To report a novel case of biopsy-proven, mass spectrometry-confirmed, wild-type transthyretin amyloidosis (ATTRwt) in nerve.
Methods: The patient was identified and evaluated in the peripheral nerve clinic. Our nerve laboratory's pathology database and the literature were searched for prior evidence of pathologically confirmed cases of ATTRwt.
Genetic and clinical features of hereditary transthyretin amyloidosis: a decade of experience at a Japanese referral center.
Orphanet J Rare Dis
September 2025
Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-0811, Japan.
Background: Hereditary transthyretin (ATTRv) amyloidosis is a rare, intractable genetic disorder caused by mutations in the transthyretin (TTR) gene. More than 150 TTR mutations have been identified, along with genotype-phenotype correlations. Early diagnosis is critical to facilitate the timely initiation of disease-modifying therapies.
View Article and Find Full Text PDFNovel method of detection of birefringent ocular amyloidosis deposits using monochromatic wavelengths of scanning laser ophthalmoscopy.
Retina
August 2025
Retina service, Wills Eye Hospital and Mid Atlantic Retina, Philadelphia, Pennsylvania.
Purpose: To describe a noninvasive imaging technique for detection of ocular amyloidosis using ultrawide field (UWF) images.
Methods: This was a retrospective, case-control study of patients with familial transthyretin (TTR) amyloidosis seen at the Wills Eye Hospital, USA and Moorfields Eye Hospital, UK. Pseudocolor, 100% red and 100% green UWF fundus images of patients with familial TTR were reviewed and, sensitivity, specificity and area under the curve (AUC) for the pattern abnormalities noted on fundus images for amyloidosis were calculated.